Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence

BACKGROUND: Patients with localized prostate cancer have historically been assigned to clinical risk groups based on local disease extent, serum prostate specific antigen (PSA), and tumor grade. Clinical risk grouping is used to determine the intensity of treatment with external beam radiotherapy (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, Anson T., Shankavaram, Uma, Trostel, Shana Y., Zhang, Hong, Sater, Houssein A., Harmon, Stephanie A., Carrabba, Nicole V., Liu, Yang, Wood, Bradford J., Pinto, Peter A., Choyke, Peter L., Stoyanova, Radka, Davicioni, Elai, Pollack, Alan, Turkbey, Baris, Sowalsky, Adam G., Citrin, Deborah E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187349/
https://www.ncbi.nlm.nih.gov/pubmed/37205576
http://dx.doi.org/10.1101/2023.05.01.23288883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187349/
https://www.ncbi.nlm.nih.gov/pubmed/37205576
http://dx.doi.org/10.1101/2023.05.01.23288883

Ejemplares similares